IMO, this analyst doesn't understand the stock at all. We are going to get 427 (Heat Shock Protein Based) results early next year .... like in February for Postate cancer than mid year or so on Bladder cancer. This drug is unpartnered and has significantly more potential than -011 as it can be targetted towards several forms (ovarian, breast, lung) of solid tumor type cancers. 427 can be a pipeline within a pipeline type of product..
If -011 Synergy trial is positive $35 PT is in the ballpark with positive P2 427 results.